.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Deloitte
Fish and Richardson
Cerilliant
Healthtrust
Chinese Patent Office
Boehringer Ingelheim
McKesson
Accenture
Julphar

Generated: July 22, 2017

DrugPatentWatch Database Preview

Hospira Company Profile

« Back to Dashboard

What is the competitive landscape for HOSPIRA, and what generic alternatives to HOSPIRA drugs are available?

HOSPIRA has five hundred and seven approved drugs.

There are seven US patents protecting HOSPIRA drugs on HOSPIRA drugs in the past three years. There are nine tentative approvals on HOSPIRA drugs.

There are sixty-six patent family members on HOSPIRA drugs in thirty-six countries.

Summary for Applicant: Hospira

Patents:7
Tradenames:326
Ingredients:200
NDAs:507
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira
VERAPAMIL HYDROCHLORIDE
verapamil hydrochloride
INJECTABLE;INJECTION070740-001May 6, 1987DISCNNoNo► Subscribe► Subscribe
Hospira
VECURONIUM BROMIDE
vecuronium bromide
INJECTABLE;INJECTION075164-002Oct 21, 1999APRXNoNo► Subscribe► Subscribe
Hospira
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
dextrose; sodium chloride
INJECTABLE;INJECTION018096-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Hospira
NITROGLYCERIN IN DEXTROSE 5%
nitroglycerin
INJECTABLE;INJECTION074083-001Oct 26, 1994DISCNNoNo► Subscribe► Subscribe
Hospira
LIDOCAINE HYDROCHLORIDE
lidocaine hydrochloride
INJECTABLE;INJECTION088329-001May 17, 1984APRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Hospira

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hospira Inc
NIPENT
pentostatin
INJECTABLE;INJECTION020122-001Oct 11, 19913,923,785► Subscribe
Hospira
TRACRIUM PRESERVATIVE FREE
atracurium besylate
INJECTABLE;INJECTION018831-001Nov 23, 19834,179,507► Subscribe
Hospira
BRETYLOL
bretylium tosylate
INJECTABLE;INJECTION017954-001Approved Prior to Jan 1, 1982RE29618► Subscribe
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-003Mar 13, 20134,910,214*PED► Subscribe
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-001Dec 17, 19995,344,840► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for HOSPIRA drugs

Drugname Dosage Strength Tradename Submissiondate
dexmedetomidine
Injection 4 mcg/mL, 20 mL vials
PRECEDEX
9/30/2015
dexmedetomidine
Injection4 mcg/mL, 50 mL and 100 mL vials
PRECEDEX
12/26/2013
argatroban in sodium chloride
Injection1 mg/mL, 50 mL vials
ARGATROBAN
12/16/2011
dexmedetomidine
Injection100 mcg/mL
PRECEDEX
4/8/2009
argatroban
Injection100 mg/mL, 2.5 mL vials
ARGATROBAN
9/24/2007

Non-Orange Book Patents for Hospira

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,436,033Methods of treatment using a dexmedetomidine premix formulation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Hospira Drugs

Country Document Number Estimated Expiration
Hungary229162► Subscribe
Taiwan201630603► Subscribe
Taiwan552136► Subscribe
Japan5927680► Subscribe
Australia2013201069► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Hospira Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB03/033United Kingdom► SubscribePRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
C0021France► SubscribePRODUCT NAME: PEGAPTANIB EN PARTICULIER SOUS FORME DE SON SEL DE SODIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/05/325/001 DU 20060131; REGISTRATION NO/DATE AT EEC: EU/1/05/325/001 DU 20060131
70017Netherlands► SubscribePRODUCT NAME: TOPOTECAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZOUT, HYDRAAT OF SOLVAAT, IN HET BIJZONDER HET HYDROCHLORI DE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 - EU/1/96/027/002 19961112; FIRST REGISTRATION: CH IKS 53857 19961016
C/GB11/055United Kingdom► SubscribePRODUCT NAME: 4-AMINOPYRIDINE OR A SALT THEREOF; REGISTERED: UK EU/1/11/699/001 20110720; UK EU/1/11/699/002 20110720
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Johnson and Johnson
Boehringer Ingelheim
Citi
Medtronic
Express Scripts
Mallinckrodt
McKinsey
Novartis
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot